IACH Focus on Leukemia 2020 | The future of MDS management
Thomas Cluzeau
• 30 Sep 2020
Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, discusses how at the moment there are not a lot of treatment options for myelodysplastic syndromes (MDS). However, in the future, there could be several treatment options for both lower and higher-risk MDS and treatment choice may depend on the molecular status of the disease. This interview took place during the 2020 Annual Meeting of the International Academy for Clinical Hematology (IACH).
Disclosures
Clinical Research: Aprea (PI GFM APR), Novartis, Alexion, Celgene/BMS, Amgen, Syros, Kartos, Arog
Advisory boards: Celgene, Abbvie, Jazz Pharma, Roche, Novartis, Agios
Education: Novartis, Amgen, Sanofi, Astellas
International congresses: Sanofi, Pfizer, Celgene, Novartis
